Stock fact sheet · data as of
Revvity, Inc. (RVTY): fair value, margin of safety and Wheel Score
Healthcare · Medical - Diagnostics & Research · United States · Blend
Is RVTY undervalued?
Revvity, Inc. (RVTY) closed at 152.17 on 16 Oct 2026, 186% above the GLS average fair value of 53.29. 9 of the 9 models that produced a number value the shares below the current price. A gap this wide usually means the market is paying for growth or a story the trailing numbers do not show yet; the models work from filed results, not forecasts, so they are conservative by design.
There is a wide gap between DDM (4.12) and DCF (108.80). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files RVTY under Blend.
Nine valuation models for RVTY
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 108.80 | -29% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 55.63 | -63% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 57.45 | -62% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 20.34 | -87% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 6.22 | -96% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 107.53 | -29% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 95.93 | -37% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | 4.12 | -97% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | 23.62 | -84% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -24.01 | -116% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 132.13 | -13% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Revvity, Inc. scores 8 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the Sunday Scan's "6 or more" rule with room to spare. A GLS Moat score of 3.0/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC 2.2%, ROE 3.3%, ROA 2.0% - with debt at 0.48 times equity and a free-cash-flow yield of 3.3%.
The dividend yield is 0.18% with a payout ratio of 13% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from Diagnostics 51%, Life Sciences 49% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 4/10 and Congressional trading 2/10 on the GLS smart-money scales.
| Piotroski F-score | 8 / 9 | ROIC | 2.2% |
|---|---|---|---|
| GLS Moat | 3.0 / 10 | ROE | 3.3% |
| Debt / equity | 0.48 | ROA | 2.0% |
| Free-cash-flow yield | 3.3% | Payout ratio | 13% |
| Institutions | 10 / 10 | Insiders · Congress | 4 · 2 / 10 |
Wheel Score 62: Fair
A Wheel Score of 62 puts Revvity, Inc. in the Fair band - below the 70 the Sunday Scan requires. Value 0/25, Health 18/20, Moat 5/15, Premium 20/20 and Stability 19/20; the weakest part is Value (0/25).
Implied volatility is 51% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 7,999 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 1.6M shares a day on a market cap of $17.0B, with a beta of 1.06; the Stability part of the Wheel Score gives that 19 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -186% margin of safety | |
| Health | 18 / 20 | Piotroski 8/9 | |
| Moat | 5 / 15 | moat 3.0/10 | |
| Premium | 20 / 20 | implied volatility 51% | |
| Stability | 19 / 20 | 1.6M shares/day, $17.0B cap, beta 1.06 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
Revvity, Inc. reports earnings on 26 Oct 2026 (before the open) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk. The shares go ex-dividend on 23 Oct 2026 (0.0700 per share), so a covered call sold before then carries a small early-assignment risk around that date.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Diagnostics & Research
The 12 companies below are the closest to Revvity, Inc. by market cap within the Medical - Diagnostics & Research industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| MEDP Medpace Holdings, Inc. | 628.60 | 504.82 | -25% | 65Good | $17.5B |
| CRL Charles River Laboratories International, Inc. | 306.24 | 137.46 | -123% | 45Weak | $14.8B |
| ICLR ICON Public Limited Company | 175.13 | 140.71 | -24% | 61Fair | $13.5B |
| GH Guardant Health, Inc. | 165.88 | - | - | 45Weak | $22.3B |
| LH Labcorp Holdings Inc. | 325.07 | 187.71 | -73% | 56Fair | $26.4B |
| DGX Quest Diagnostics Incorporated | 239.01 | 149.02 | -60% | 58Fair | $26.4B |
| QGEN Qiagen N.V. | 45.56 | 34.12 | -34% | 62Fair | $9.4B |
| MTD Mettler-Toledo International Inc. | 1,639.04 | 647.54 | -153% | 60Fair | $32.8B |
| ILMN Illumina, Inc. | 267.93 | 113.15 | -137% | 58Fair | $40.5B |
| WAT Waters Corporation | 436.91 | 85.55 | -411% | 57Fair | $42.9B |
| IDXX IDEXX Laboratories, Inc. | 547.18 | 377.99 | -45% | 70Good | $43.1B |
| IQV IQVIA Holdings Inc. | 271.04 | 193.82 | -40% | 65Good | $44.6B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about RVTY
Is RVTY undervalued right now?
No: at 152.17 the stock trades 186% above the GLS average fair value of 53.29 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of RVTY and what does it mean?
RVTY scores 62 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for RVTY?
53.29 per share as of 16 Oct 2026 - the simple average of the 9 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Revvity, Inc. report earnings next?
The next earnings report is due on 26 Oct 2026 (before the open), 10 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does RVTY have listed options, and how liquid are they?
Yes. The nightly snapshot found 390 listed contracts with 7,999 open interest across all expiries and implied volatility of 51% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.